NASDAQ:MNPR Monopar Therapeutics (MNPR) Stock Price, News & Analysis $0.72 +0.07 (+10.69%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.64▼$0.7350-Day Range$0.61▼$0.9452-Week Range$0.27▼$1.73Volume116,675 shsAverage Volume2.44 million shsMarket Capitalization$12.76 millionP/E RatioN/ADividend YieldN/APrice Target$2.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Monopar Therapeutics alerts: Email Address Monopar Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside175.9% Upside$2.00 Price TargetShort InterestHealthy0.67% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.39Based on 3 Articles This WeekInsider TradingAcquiring Shares$61,376 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.37) to ($0.35) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.80 out of 5 starsMedical Sector243rd out of 936 stocksPharmaceutical Preparations Industry109th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingMonopar Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMonopar Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Monopar Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.67% of the float of Monopar Therapeutics has been sold short.Short Interest Ratio / Days to CoverMonopar Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Monopar Therapeutics has recently decreased by 29.23%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMonopar Therapeutics does not currently pay a dividend.Dividend GrowthMonopar Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MNPR. Previous Next 3.6 News and Social Media Coverage News SentimentMonopar Therapeutics has a news sentiment score of 1.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Monopar Therapeutics this week, compared to 1 article on an average week.Search Interest4 people have searched for MNPR on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Monopar Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $61,376.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders41.60% of the stock of Monopar Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.83% of the stock of Monopar Therapeutics is held by institutions.Read more about Monopar Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Monopar Therapeutics are expected to grow in the coming year, from ($0.37) to ($0.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Monopar Therapeutics is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Monopar Therapeutics is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMonopar Therapeutics has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Monopar Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.In answer to this issue, we have released a Special Report to the public. About Monopar Therapeutics Stock (NASDAQ:MNPR)Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Read More MNPR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MNPR Stock News HeadlinesJuly 24 at 10:49 PM | markets.businessinsider.comMonopar Therapeutics Inc: Positioned for Growth with Strategic Radiopharmaceutical Pivot and Promising Preclinical DataJuly 17, 2024 | americanbankingnews.comMonopar Therapeutics (NASDAQ:MNPR) Shares Up 4.1%July 26, 2024 | Porter & Company (Ad)Obama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” June 25, 2024 | globenewswire.comMonopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM'24June 11, 2024 | globenewswire.comMonopar and NorthStar Amend & Extend CollaborationJune 10, 2024 | globenewswire.comMonopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual MeetingJune 5, 2024 | investorplace.comPenny Stocks That Insiders Are Loading Up On: 3 Names to Watch CloselyMay 24, 2024 | finanznachrichten.deMonopar Therapeutics Inc.: Monopar Announces CFO SuccessionJuly 26, 2024 | Porter & Company (Ad)Obama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” May 24, 2024 | markets.businessinsider.comMonopar Therapeutics: CFO Kim Tsuchimoto To Retire - Quick FactsMay 24, 2024 | globenewswire.comMonopar Announces CFO SuccessionMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Monopar Therapeutics on Strategic Shift and Pipeline PotentialMay 9, 2024 | investorplace.comMNPR Stock Earnings: Monopar Therapeutics Beats EPS for Q1 2024May 9, 2024 | finanznachrichten.deMonopar Therapeutics Inc.: Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma PipelineMay 9, 2024 | markets.businessinsider.comMonopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma PipelineMay 9, 2024 | globenewswire.comMonopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma PipelineMay 1, 2024 | investing.comMonopar Therapeutics Inc (MNPR)April 18, 2024 | globenewswire.comMonopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual MeetingSee More Headlines Receive MNPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Monopar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MNPR CUSIPN/A CIK1645469 Webwww.monopartx.com Phone847-388-0349FaxN/AEmployees9Year Founded2014Price Target and Rating Average Stock Price Target$2.00 High Stock Price Target$2.00 Low Stock Price Target$2.00 Potential Upside/Downside+177.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,400,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-110.42% Return on Assets-86.33% Debt Debt-to-Equity RatioN/A Current Ratio6.21 Quick Ratio6.21 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.38 per share Price / Book1.89Miscellaneous Outstanding Shares17,600,000Free Float10,211,000Market Cap$12.67 million OptionableNot Optionable Beta1.18 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Chandler D. Robinson M.B.A. (Age 40)M.D., M.Sc., MBA, MSc, Co-Founder, CEO, President & Director Comp: $710.5kMs. Kim R. Tsuchimoto CPA (Age 61)CFO, Secretary, Treasurer & Director Comp: $354kMr. Andrew J. Cittadine M.B.A. (Age 51)Chief Operating Officer Comp: $416.7kDr. Patrice P. Rioux M.D. (Age 73)Ph.D., Acting Chief Medical Officer Key CompetitorsMoleculin BiotechNASDAQ:MBRXEdesa BiotechNASDAQ:EDSAProteostasis TherapeuticsNASDAQ:PTIBioXcel TherapeuticsNASDAQ:BTAIKezar Life SciencesNASDAQ:KZRView All CompetitorsInsidersAndrew CittadineBought 20,508 shares on 6/20/2024Total: $15,175.92 ($0.74/share)Andrew CittadineBought 12,000 shares on 6/17/2024Total: $10,800.00 ($0.90/share)Andrew CittadineBought 12,000 shares on 6/13/2024Total: $10,920.00 ($0.91/share)Andrew CittadineBought 12,000 shares on 6/3/2024Total: $9,120.00 ($0.76/share)Andrew CittadineBought 12,000 shares on 5/31/2024Total: $7,680.00 ($0.64/share)View All Insider Transactions MNPR Stock Analysis - Frequently Asked Questions How have MNPR shares performed this year? Monopar Therapeutics' stock was trading at $0.3402 at the start of the year. Since then, MNPR shares have increased by 113.1% and is now trading at $0.7249. View the best growth stocks for 2024 here. How were Monopar Therapeutics' earnings last quarter? Monopar Therapeutics Inc. (NASDAQ:MNPR) released its quarterly earnings results on Thursday, May, 9th. The company reported ($0.10) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.07. Does Monopar Therapeutics have any subsidiaries? Monopar Therapeutics subsidiaries include these companies: Monopar Therapeutics Pty Ltd, and Monopar Therapeutics SARL. When did Monopar Therapeutics IPO? Monopar Therapeutics (MNPR) raised $9 million in an IPO on Thursday, December 19th 2019. The company issued 1,100,000 shares at a price of $8.00 per share. JonesTrading served as the underwriter for the IPO and Arcadia Securities was co-manager. How do I buy shares of Monopar Therapeutics? Shares of MNPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Monopar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Monopar Therapeutics investors own include Entasis Therapeutics (ETTX), Fulcrum Therapeutics (FULC), Sorrento Therapeutics (SRNE), Akero Therapeutics (AKRO), Chimerix (CMRX), Trevena (TRVN). This page (NASDAQ:MNPR) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monopar Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monopar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.